Milad Nadia, Belisario Kyla, MacKillop James, Hirota Jeremy A
Firestone Institute for Respiratory Health - Division of Respirology, Department of Medicine, McMaster University.
McMaster Immunology Research Centre, McMaster University.
Cannabis. 2024 Dec 12;7(3):177-192. doi: 10.26828/cannabis/2024/000248. eCollection 2024.
The potential impact of cigarette and cannabis smoking on COVID-19 infection outcomes is not well understood. We investigated the association between combustible tobacco use and dried cannabis use with COVID-19 infection in a longitudinal cohort of community adults.
The sample comprised 1,343 participants, originally enrolled in 2018, who reported their cigarette and cannabis use in 11 assessments over 44 months, until 2022. COVID-19 infection history were self-reported after the onset of the pandemic. Univariate and multivariate logistic regression analyses were performed. The potentially confounding factor of vaccination status was also considered by stratifying data by booster vaccination self-reporting.
Among 1,343 participants, 820 (61.1%) reported any COVID-19 infection. Dried cannabis use (46.3% of participants, = 721) was associated with higher self-reporting of 2+ COVID-19 infections (13.3% vs. 7.3% in non-users, = .0004), while tobacco use (18.5% of participants, = 248) had no significant effect (13.3% vs. 10.0% in no use group, = .116). When stratified into single or dual substance use groups, dried cannabis-only use was associated with increased reporting of 1 or 2+ COVID-19 infections compared to substance non-users, while tobacco-only use and dual use groups were not significantly different from non-users. To account for differences in vaccination rates between substance use groups, we found that, among individuals with a COVID-19 booster vaccine, dried cannabis use was still associated with increased reporting of 2+ COVID-19 infections ( = .008).
Our study suggests that dried cannabis use is associated with a higher likelihood of reporting 2+ COVID-19 infections. Although the study was observational and relied on self-report infection status, our findings support the need for further investigation into the impact of cannabis use on COVID-19 infection, particularly studies employing controlled experimental designs.
香烟和大麻吸食对新冠病毒感染结果的潜在影响尚未得到充分了解。我们在一个社区成年人纵向队列中,研究了可燃烟草使用和干大麻使用与新冠病毒感染之间的关联。
样本包括1343名参与者,他们最初于2018年入组,在44个月内的11次评估中报告了自己的香烟和大麻使用情况,直至2022年。新冠病毒感染史在疫情爆发后由参与者自行报告。进行了单变量和多变量逻辑回归分析。还通过根据加强疫苗接种自我报告对数据进行分层,考虑了疫苗接种状况这一潜在混杂因素。
在1343名参与者中,820人(61.1%)报告有任何新冠病毒感染。使用干大麻的参与者(占参与者的46.3%,n = 721)报告有2次及以上新冠病毒感染的比例更高(13.3%,而非使用者为7.3%,p = 0.0004),而烟草使用(占参与者的18.5%,n = 248)没有显著影响(不使用组为13.3%,无使用组为10.0%,p = 0.116)。当分为单一或双重物质使用组时,与不使用物质的参与者相比,仅使用干大麻与报告1次或2次及以上新冠病毒感染的比例增加有关,而仅使用烟草组和双重使用组与不使用物质的参与者没有显著差异。为了考虑物质使用组之间疫苗接种率的差异,我们发现,在接种了新冠病毒加强疫苗的个体中,使用干大麻仍与报告2次及以上新冠病毒感染的比例增加有关(p = 0.008)。
我们的研究表明,使用干大麻与报告2次及以上新冠病毒感染的可能性更高有关。尽管该研究是观察性的且依赖于自我报告的感染状况,但我们的研究结果支持有必要进一步调查大麻使用对新冠病毒感染的影响,特别是采用对照实验设计的研究。